menu
    • menu

    Company profile for Veralox Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are developing first-in-class small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.Veralox is developing a disease-modifying therapy for Type 1 diabetes, another immune-driven pathology. In Type 1 diabetes patients, an abn...
    We are developing first-in-class small molecule therapeutics that treat the underlying pathologies of thrombosis and type 1 diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.Veralox is developing a disease-modifying therapy for Type 1 diabetes, another immune-driven pathology. In Type 1 diabetes patients, an abnormal immune response results in damage and destruction to insulin-producing pancreatic β-cells. Inflammatory signals increase the expression of 12-LOX, leading to an overabundance of 12-HETE. 12-HETE stresses β-cells

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Veralox TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    4539 Metropolitan Ct. Frederick, MD 21704
    Telephone
    Telephone
    301-360-3502
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://veralox.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/veralox-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Veralox Expands Pipeline With Option To Acquire Nudge Therapeutics
    Veralox Expands Pipeline With Option To Acquire Nudge Therapeutics

    09 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics-302347548.html

    PR NEWSWIRE
    09 Jan 2025
    Share Share
    Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005
    Veralox Therapeutics Announces EMA Orphan Drug Designation for VLX-1005

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2929964/0/en/Veralox-Therapeutics-Announces-EMA-Orphan-Drug-Designation-for-VLX-1005.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Veralox Names Jonathan Mow as CEO as the Company Advances Development
    Veralox Names Jonathan Mow as CEO as the Company Advances Development

    20 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/20/2690909/0/en/Veralox-Names-Jonathan-Mow-as-Chief-Executive-Officer-as-the-Company-Advances-Development-of-First-in-Class-Therapies-for-Immune-Mediated-Diseases-in-Conjunction-with-Financing.html

    GLOBENEWSWIRE
    20 Jun 2023
    Share Share
    Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer
    Veralox Therapeutics Appoints Lisa Beck as Chief Business Officer

    23 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/veralox-therapeutics-appoints-lisa-beck-as-chief-business-officer-301488151.html

    PRNEWSWIRE
    23 Feb 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search